Loading clinical trials...
Loading clinical trials...
Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)
Conditions
Interventions
bispecific antibody 4G7xH22
sargramostim
Locations
1
United States
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States
Start Date
September 28, 2000
Primary Completion Date
February 14, 2003
Completion Date
February 14, 2003
Last Updated
May 3, 2018
NCT00106925
NCT06311227
NCT06337318
NCT07388563
NCT05139017
NCT06285890
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions